{"schema":"sb.node.v1","id":"sb:e/ceb4a3e9856ac4dc6947fcfd","kind":"entity","label":{"text":"private securities litigation","locale":"en"},"identity":{"anchor":"label:en:private securities litigation","strength":"label"},"asOf":{"knowledgeCutoff":"2026-10-08T23:32:17.032179+00:00","snapshot":"deploy c7c9e8c8587abb7817ca7008e43df7100ad13907"},"lens":{"kind":"public"},"build":{"plane":"projected","builtFrom":["entity_graph.slim.json","entity_receipts (deploy asset)","event_graph.json","truth_records (deploy asset)","corroborated_record.json"],"rule":"node-projection.entity@v1"},"standing":{"evidence":{"supporting":79,"separatePublishers":9,"basis":"documents that mention the subject and the outlets that carried them; a mention is evidence the referent is in use, not evidence about any claim"},"admission":{"state":"provisional","reason":"entity graph provenance 'observed'; the node carries no promotion receipt in v1","policy":"EQ-PROMOTION (receipt not carried)"},"disposition":{"state":"served","reason":"public record"},"validity":{"from":"2026-09-04","to":"2026-10-08","basis":"first and last day we saw it mentioned; not the subject's own lifetime"},"measurement":{"state":"partial","blind":["assertion coverage 0.481: about 52% of mentions carry no typed assertion"]}},"dimensions":{"domains":["private_equity","deal_primary","commercial_real_estate","canada"],"activeDays":25,"assertions":{"launch-release":20,"acquisition":8,"regulatory-approval":3,"legal-ruling":3,"meeting-visit":1,"price-threshold":1}},"up":[],"upNote":"An entity is a root: it is contained by nothing. Pan out by following R.","children":{"count":12,"byKind":{"observation":12},"items":[{"id":"sb:o/db8ad5fbb15e1c9754a02d94","kind":"observation","label":"PR Newswire · 2026-10-08 · Viatris Agrees to Acquire Pacira BioSciences, Advancing Its Innovative Medicines Strategy and Becoming a Leader in Non-Opioid Pain Therapies","url":"https://www.prnewswire.com/news-releases/viatris-agrees-to-acquire-pacira-biosciences-advancing-its-innovative-medicines-strategy-and-becoming-a-leader-in-non-opioid-pain-therapies-302902353.html"},{"id":"sb:o/c5bb04d7462e1081571eb82f","kind":"observation","label":"Financial Post · 2026-10-08 · TG Therapeutics Announces Schedule of Data Presentations at MSToronto2026","url":"https://financialpost.com/pmn/business-wire-news-releases-pmn/tg-therapeutics-announces-schedule-of-data-presentations-at-mstoronto2026"},{"id":"sb:o/58e76c465a09694cff9a34bf","kind":"observation","label":"Latest News · 2026-10-08 · Physician Research Points to a New Frontier for Stemtech Corporation: Nutritional Activation of the Body's Endogenous Regenerative System | STEK Stock News","url":"https://www.stocktitan.net/news/STEK/physician-research-points-to-a-new-frontier-for-stemtech-corporation-oljnuju3iq83.html"},{"id":"sb:o/04c3bcd10d1cce57e04f45ee","kind":"observation","label":"PR Newswire · 2026-10-08 · Eminence Grey and Lumen Partner to Deliver Sovereign AI Infrastructure Across the U.S.","url":"https://www.prnewswire.com/news-releases/eminence-grey-and-lumen-partner-to-deliver-sovereign-ai-infrastructure-across-the-us-302901935.html"},{"id":"sb:o/cec90c7c1bf64d5f2d3015f0","kind":"observation","label":"itweb.co.za · 2026-10-07 · New Global Survey Finds Majority of VMware Users Are Choosing Alternative Paths for Cost Control, Roadmap Flexibility and Better Support","url":"https://www.itweb.co.za/article/new-global-survey-finds-majority-of-vmware-users-are-choosing-alternative-paths-for-cost-control-roadmap-flexibility-and-better-support/DZQ58vV8gVwMzXy2"},{"id":"sb:o/302be7536e977b7d759d3afd","kind":"observation","label":"IBM · 2026-10-07 · IBM and Red Hat Remediate More Than 400 Previously Unknown Open Source Vulnerabilities","url":"https://newsroom.ibm.com/2026-10-06-ibm-and-red-hat-remediate-more-than-400-previously-unknown-open-source-vulnerabilities"},{"id":"sb:o/b28ef0a29cb788814e4772d7","kind":"observation","label":"PR Newswire · 2026-10-07 · FibroBiologics Files Patent Application for Technology Designed to Produce GLP-1 and Other Therapeutic Peptides Inside the Body","url":"https://www.prnewswire.com/news-releases/fibrobiologics-files-patent-application-for-technology-designed-to-produce-glp-1-and-other-therapeutic-peptides-inside-the-body-302901121.html"},{"id":"sb:o/e5ef8857b699233791fbf5d1","kind":"observation","label":"PR Newswire · 2026-10-07 · AbbVie's Telisotuzumab Adizutecan (Temab-A) Receives Two Breakthrough Therapy Designations From the U.S. FDA for CRC and NSCLC","url":"https://www.prnewswire.com/news-releases/abbvies-telisotuzumab-adizutecan-temab-a-receives-two-breakthrough-therapy-designations-from-the-us-fda-for-crc-and-nsclc-302900512.html"},{"id":"sb:o/7714e2498ee2fd895e1e8f3a","kind":"observation","label":"PR Newswire · 2026-10-06 · TORM plc announces pricing of secondary public offering of its class A common shares","url":"https://www.prnewswire.com/news-releases/torm-plc-announces-pricing-of-secondary-public-offering-of-its-class-a-common-shares-302899740.html"},{"id":"sb:o/4f437593930930c15a56e3e2","kind":"observation","label":"PR Newswire · 2026-10-06 · DarioHealth Announces Independent Aon Analysis that Supports Estimated 2.5%-7.2% In-Year Reduction in Total Healthcare Costs","url":"https://www.prnewswire.com/news-releases/dariohealth-announces-independent-aon-analysis-that-supports-estimated-2-57-2-in-year-reduction-in-total-healthcare-costs-302897540.html"}],"cursor":"c1.eyJpZCI6InNiOmUvY2ViNGEzZTk4NTZhYzRkYzY5NDdmY2ZkIiwibCI6ImNoaWxkcmVuIiwibyI6MTAsImsiOm51bGwsImEiOiIyMDI2LTEwLTA4VDIzOjMyOjE3LjAzMjE3OSswMDowMCJ9","order":"newest first; we keep the 12 newest receipts for this entity. Its other observations are counted in standing.evidence.supporting but are not addressable in v1"},"relations":{"count":10,"byKind":{"co-mentioned":10},"items":[{"kind":"relation","label":"co-mentioned with reform act (79 documents)","role":"co-mentioned","relationKind":"co-mentioned","members":2,"id":"sb:r/58076c77a18c8eb1b8f6fd99"},{"kind":"relation","label":"co-mentioned with forward-looking statements (75 documents)","role":"co-mentioned","relationKind":"co-mentioned","members":2,"id":"sb:r/2a3b0ac0f6ed5b00f2e2b5ba"},{"kind":"relation","label":"co-mentioned with sec (63 documents)","role":"co-mentioned","relationKind":"co-mentioned","members":2,"id":"sb:r/ebcddf3c23c08f516ff51380"},{"kind":"relation","label":"co-mentioned with prnewswire (59 documents)","role":"co-mentioned","relationKind":"co-mentioned","members":2,"id":"sb:r/2389a934cfeda5d99037f224"},{"kind":"relation","label":"co-mentioned with exchange commission (51 documents)","role":"co-mentioned","relationKind":"co-mentioned","members":2,"id":"sb:r/d328f981c6ebc901482e2fab"},{"kind":"relation","label":"co-mentioned with nasdaq (41 documents)","role":"co-mentioned","relationKind":"co-mentioned","members":2,"id":"sb:r/8362c932a2c8332baa3c8884"},{"kind":"relation","label":"co-mentioned with risk factors (40 documents)","role":"co-mentioned","relationKind":"co-mentioned","members":2,"id":"sb:r/7f97e3581fcd873242160e12"},{"kind":"relation","label":"co-mentioned with u.s. securities (31 documents)","role":"co-mentioned","relationKind":"co-mentioned","members":2,"id":"sb:r/d1fe265d1e0faad3a3a6cf82"},{"kind":"relation","label":"co-mentioned with nyse (27 documents)","role":"co-mentioned","relationKind":"co-mentioned","members":2,"id":"sb:r/c059cd969fe3edd49bb11993"},{"kind":"relation","label":"co-mentioned with united states (27 documents)","role":"co-mentioned","relationKind":"co-mentioned","members":2,"id":"sb:r/c971fd9c9a982cc7592c68f7"}],"cursor":null,"order":"situations first, then claims (the subject's own maintained record, then site-wide corroborated clusters; each label ends with its standing), then co-mentions by shared documents, descending. Co-mentions are the ten strongest the entity graph keeps per entity"},"edge":{"state":"continues"},"links":{"rest":"/api/v1/node/e/ceb4a3e9856ac4dc6947fcfd","mcp":"traverse {\"id\":\"sb:e/ceb4a3e9856ac4dc6947fcfd\"}","page":"/entity/private-securities-litigation/"},"limits":{"levelsPerCall":1,"pageSize":10,"maxPageSize":50,"membersMax":50,"statement":"One level per call: depth is 1 and only 1, and there is no whole-graph dump. pageSize 1-50 (default 10); a page limit is a cursor, never an edge. Members are listed up to 50. At most 60 traverse calls a minute per caller (runaway-loop protection, not a meter). One knowledge cutoff is served: the deploy's."},"actions":[{"verb":"unfold","lit":true,"effect":"read","layer":"cantina","call":"traverse {\"id\":\"sb:e/ceb4a3e9856ac4dc6947fcfd\",\"level\":\"children\"}"},{"verb":"fold","lit":true,"effect":"read","layer":"cantina","call":"traverse {\"id\":\"sb:e/ceb4a3e9856ac4dc6947fcfd\"}"},{"verb":"panOut","lit":false,"effect":"read","layer":"cantina","reason":"An entity is a root: it is contained by nothing. Pan out by following R."},{"verb":"follow","lit":true,"effect":"read","layer":"cantina","call":"traverse {\"id\":\"sb:e/ceb4a3e9856ac4dc6947fcfd\",\"level\":\"relations\"}"},{"verb":"receipts","lit":false,"effect":"read","layer":"cantina","reason":"receipts are the observations below this node; unfold to reach them"},{"verb":"edge","lit":true,"effect":"read","layer":"cantina","call":"traverse {\"id\":\"sb:e/ceb4a3e9856ac4dc6947fcfd\"}"},{"verb":"asOf","lit":false,"effect":"read","layer":"cantina","reason":"v1 serves one knowledge cutoff, this deploy's; walking an earlier cutoff needs retained history (EQ-REPLAY), which v1 does not keep"},{"verb":"switchObserver","lit":false,"effect":"read","layer":"cantina","reason":"the public record is the same for every observer; traversal through a Watch's lens is not served in v1"},{"verb":"readOriginal","lit":false,"effect":"read","layer":"cantina","reason":"no translation is applied on this node; every label is the source's own text"},{"verb":"save","lit":false,"effect":"watch-declaration","layer":"workshop","reason":"saving applies to a configured Watch; configure one around this node first (free), then save it"},{"verb":"deliver","lit":false,"effect":"watch-declaration","layer":"workshop","reason":"delivery applies to a saved Watch"},{"verb":"format","lit":false,"effect":"watch-declaration","layer":"workshop","reason":"output format applies to a saved Watch"},{"verb":"deltaR","lit":false,"effect":"read","layer":"workshop","reason":"Delta R needs a saved Watch with a previous reading"},{"verb":"read","lit":false,"effect":"read","layer":"docking-bay","reason":"one-time Reads are parked until the Commander decides their shape (#938)"}]}